Jiya Acquisition Corp.
| IPO Proceeds, $M | $103.52M |
|---|---|
| IPO Date | Nov 19, 2020 |
| CEO | Rekha Hemrajani |
| Left Lead | Citigroup |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biopharmaceuticals |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Nov 25, 2022 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Jiya Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 7 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Srinivas Akkaraju, M.D., Ph.D. | 52 | Chairman |
| Rekha Hemrajani | 51 | Director and Chief Executive Officer |
| Richard Van Doren | 43 | Director, Secretary and Chief Financial Officer |
| Cory Freedland, Ph.D. | 44 | Director and Chief Investment Officer |
| Dr. Pamela Klein | 58 | Director |
| Daniel Spiegelman | 61 | Director |
| Dr. Steve Kelsey | 58 | Director |
| Dr. Lori Friedman, Ph.D. | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Citigroup | BR | 10,000,000 | units |
| 10,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Nov 2, 2020 | Initial S-1 |
| Nov 16, 2020 |
S-1/A Amendment #1
Sign In to view filing content. |
| Nov 18, 2020 |
PR announcing pricing of $100mm IPO
Sign In to view filing content. |
| Nov 20, 2020 | 424B4 IPO Prospectus |
| Dec 10, 2020 |
8-K announcing partial over-allotment exercise
Sign In to view filing content. |
| Sep 24, 2021 |
8-K announcing change in directors
Sign In to view filing content. |
| Sep 9, 2022 |
8-K announcing change in officers
Sign In to view filing content. |